<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746342</url>
  </required_header>
  <id_info>
    <org_study_id>MSSC-G004</org_study_id>
    <nct_id>NCT01746342</nct_id>
  </id_info>
  <brief_title>Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial</brief_title>
  <acronym>SAMSPAP</acronym>
  <official_title>A Randomized, Controlled, Clinical Trial of Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea-Hypopnea in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Multiple Sclerosis Society of Canada (Primary funding agency)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>VitalAire Incorporated (Respiratory Therapist time)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fatigue is highly prevalent among multiple sclerosis (MS) patients and has pervasive adverse&#xD;
      effects on daily functioning and quality of life. The investigators found in a recent study&#xD;
      that obstructive sleep apnea-hypopnea (OSAH) is the most common sleep abnormality in multiple&#xD;
      sclerosis (MS) patients. There was also a significant relationship between OSAH and higher&#xD;
      fatigue scores in MS patients. Preliminary work from the investigators in this group of&#xD;
      subjects shows that treatment of sleep disorders (mostly OSAH) can improve fatigue and other&#xD;
      symptoms in some MS patients. However, it is now necessary to systemically test the effect of&#xD;
      OSAH treatment in a randomized, controlled study, to be sure that it really does improve&#xD;
      fatigue and other symptoms. The best treatment for OSAH in the general population is&#xD;
      continuous positive airway pressure (CPAP). This treatment has been well tolerated by most MS&#xD;
      patients who have used the device at the investigators' center. This project will therefore&#xD;
      be a randomized, controlled, clinical trial of CPAP in MS patients with OSAH. The effects of&#xD;
      six months of CPAP treatment on fatigue as well as sleep quality, somnolence, pain,&#xD;
      disability, and quality of life will be studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue Severity Scale</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue Scale for Motor and Cognitive Functions</measure>
    <time_frame>Three &amp; Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>Three &amp; Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index</measure>
    <time_frame>Three &amp; Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain visual analog scale</measure>
    <time_frame>Three &amp; Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis-specific quality of life measure-54 (MSQOL-54)</measure>
    <time_frame>Three &amp; Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale</measure>
    <time_frame>Three months</time_frame>
    <description>Primary outcome measure is FSS at six months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>Three &amp; Six months</time_frame>
    <description>Standard scale for evaluation of Multiple Sclerosis-related disease disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Center for Epidemiological Studies-Depression Scale</measure>
    <time_frame>Three &amp; Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive evaluation</measure>
    <time_frame>Six months</time_frame>
    <description>Montreal Cognitive Assessment (MoCA) and Tower of London-Drexel University</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polysomnographic variables</measure>
    <time_frame>Six months</time_frame>
    <description>Standard complete polysomnographic measures of sleep and respiration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective CPAP compliance</measure>
    <time_frame>Three and Six Months</time_frame>
    <description>Standard measures of CPAP use and efficacy from machine microprocessor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Obstructive Sleep Apnea-hypopnea in Multiple Sclerosis Patients</condition>
  <arm_group>
    <arm_group_label>Effective CPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous positive airway pressure: effective fixed level determined by polysomnographic titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham CPAP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Continuous positive airway pressure device modified by manufacturer to deliver minimal pressure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Effective continuous positive airway pressure (CPAP)</intervention_name>
    <arm_group_label>Effective CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham continuous positive airway pressure (CPAP)</intervention_name>
    <arm_group_label>Sham CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of multiple sclerosis by a neurologist based on standard criteria (Annals&#xD;
             Neurol 2011; 69:292-302)&#xD;
&#xD;
          -  Expanded Disability Status Scale score of 0 to 7.0&#xD;
&#xD;
          -  MS-relapse free for &gt;30 days prior to screening&#xD;
&#xD;
          -  Pittsburgh sleep quality Index &gt; 5&#xD;
&#xD;
          -  Fatigue Severity Scale score &gt;=4&#xD;
&#xD;
          -  Montreal Cognitive Assessment (MoCA) &gt;= 26&#xD;
&#xD;
          -  diagnosis of OSAH by polysomnography showing AHI &gt;= 15 events/h of sleep&#xD;
&#xD;
          -  forced vital capacity &gt;60% predicted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy or planned pregnancy&#xD;
&#xD;
          -  psychiatric conditions which could preclude compliance with informed consent, study&#xD;
             procedures, or study requirements&#xD;
&#xD;
          -  other significant neurological, pulmonary, otorhinological, and medical disorders&#xD;
&#xD;
          -  major depression within the past year&#xD;
&#xD;
          -  any value of &gt;1.5 times the upper limit or &lt;0.75 the lower limit of the reference&#xD;
             range for any standard clinical hemogram and biochemistry determinations which is&#xD;
             clinically significant&#xD;
&#xD;
          -  current treatment for OSAH&#xD;
&#xD;
          -  presence of another untreated sleep disorder which is clinically significant&#xD;
&#xD;
          -  very severe OSAH (safety criterion)defined as an AHI &gt;30 with either a 4% O2&#xD;
             desaturation index &gt;15 events/h OR work in a safety-critical position OR an ESS score&#xD;
             &gt;=15&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kimoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daria Trojan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 6, 2012</study_first_submitted>
  <study_first_submitted_qc>December 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2012</study_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University</investigator_affiliation>
    <investigator_full_name>Dr John Kimoff</investigator_full_name>
    <investigator_title>Co-Principal Investigator: with Dr Daria Trojan</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

